deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT01428635

Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy

Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF)

Sponsor: M.D. Anderson Cancer Center

Conditions Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Primary Myelofibrosis Thrombocytopenia
Interventions Eltrombopag Olamine
Updated 15 times since 2017 Last updated: Sep 6, 2023 Started: Jan 13, 2012 Primary completion: Jan 3, 2022 Completion: Jan 3, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01428635, this PHASE2/PHASE3 trial focuses on Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 15 times since 2012, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Jun 2019 · 7 months · monthly snapshot~Jun 2019 – ~Oct 2019 · 4 months · monthly snapshot~Oct 2019 – ~Aug 2020 · 10 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Feb 2022 · 12 months · monthly snapshot~Feb 2022 – ~Mar 2023 · 13 months · monthly snapshot~Mar 2023 – ~Oct 2023 · 7 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  3. Oct 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  4. Mar 2023 — Oct 2023 [monthly]

    Completed PHASE2_PHASE3

  5. Feb 2022 — Mar 2023 [monthly]

    Completed PHASE2_PHASE3

    Status: Active Not Recruiting → Completed

▶ Show 10 earlier versions

  1. Feb 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  2. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  3. Aug 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2_PHASE3

  4. Oct 2019 — Aug 2020 [monthly]

    Active Not Recruiting PHASE2_PHASE3

    Phase: PHASE2 → PHASE2_PHASE3

  5. Jun 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Nov 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  8. Jul 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  9. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations